The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
International medical graduates (IMGs) in leadership roles within academic oncology in the United States (US).
 
Shipra Gandhi
Honoraria - Aptitude Health; OncLive/MJH Life Sciences
Consulting or Advisory Role - AstraZeneca; Hologic/Biotheranostics; MedPage Today; Novartis; Peerview
Speakers' Bureau - Roche
Travel, Accommodations, Expenses - MJH Life Sciences; Roche
 
Jayasree Krishnan
No Relationships to Disclose
 
Tarrant McPherson
No Relationships to Disclose
 
Maria Hafez
No Relationships to Disclose
 
Kriti Mittal
Honoraria - Aptitude Health; Cardinal Health; IntrinsiQ; Medpage; Research to Practice; Research to Practice; Targeted Oncology; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Aveo; AVEO; Curio Science; Dendreon; Janssen; Myovant Sciences
Research Funding - Pfizer
 
Abhishek Kumar
Stock and Other Ownership Interests - Abbvie; ACADIA Pharmaceuticals; ADMA Biologics; Agenus; Agenus; Agios; AIkido Pharma; Albireo Pharma; Amazon; Amgen; AstraZeneca; AVEO; BeyondSpring Pharmaceuticals; Bio-Path Holdings, Inc; BioTelemetry; Blueprint Medicines; Bristol-Myers Squibb; Cara Therapeutics; Cardiff Oncology; Celgene; ChemBio Diagnostic Systems; Contrafect; crispr therapeutics; CryoLife; CUE Biopharma; CVS Health; DermTech; Editas Medicine; Fidelity 500; Five Prime Therapeutics; Geron; Gevo; Global Medical; Google; IDEXX Laboratories; Immunomedics; Invesco S&P; Iovance Biotherapeutics; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Kronos; Lilly; Livongo; Medtronic; Moderna Therapeutics; Northwest Biotherapeutics; Novavax; Ontrak; Pfizer; Poseida Therapeutics; Precision Biosciences; Protagonist Therapeutics; PTC Therapeutics; Purple Biotech; Regeneron; Renalytix AI PLC; Schrodinger; Sensei Biotherapeutics; Sierra Oncology; SOC Telemed; SPDR S and P Biotech ETF; Spectrum Pharmaceuticals; Surgalign; Teladoc; Trovagene; Uniqure; VBI Vaccines; Vericel; Vertex; Viatris; Viking Therapeutics
Research Funding - Napo Pharmaceuticals
Travel, Accommodations, Expenses - ASCO
 
Marianne Dubard-Gault
Stock and Other Ownership Interests - Illumina (I)
 
Anusha Chidharla
No Relationships to Disclose
 
Hussain Rangoonwala
No Relationships to Disclose
 
Mrinalini Ramesh
No Relationships to Disclose
 
Minaam Abid
No Relationships to Disclose
 
Raj Patel
No Relationships to Disclose
 
Alexander Gavralidis
No Relationships to Disclose
 
Ronit Juthani
No Relationships to Disclose
 
Mariana Chavez-MacGregor
No Relationships to Disclose
 
Taofeek Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES; Coherus Biosciences; GenCart; Taobob LLC
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Coherus Biosciences; Daichi; Eisai; Eisai; EMD Serono; Exelixis; G1 Therapeutics; Heat Biologics; Ipsen; Janssen; Jazz Pharmaceuticals; Lilly; MedImmune; Merck; Meryx Pharmaceuticals; Novartis; PharmaMar; Puma Biotechnology; Roche/Genentech; Takeda; Triptych Health Partners; Xcovery
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals; G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Loxo/Lilly (Inst); Merck (Inst); Meryx Pharmaceuticals (Inst); Novartis (Inst); Oncorus (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen
Other Relationship - EMD Serono; Novartis; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Ziad Bakouny
Honoraria - UpToDate
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
(OPTIONAL) Uncompensated Relationships - ASCO IMG Community of Practice; Dana-Farber Cancer Institute; IMG Oncologists (NGO)
 
Nazli Dizman
Stock and Other Ownership Interests - Several pharmaceutical companies (I)
Consulting or Advisory Role - Vivreon Biosciences
 
Toni Choueiri
Leadership - ASCO
Stock and Other Ownership Interests - Abalytics Oncology; Bicycle Therapeutics; Curesponse; Faron Pharmaceuticals; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; MashupMD; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bicycle Therapeutics; Bristol-Myers Squibb; Clinical Care Options; Curesponse; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - OTHER MEDICAL COMMUNICATION COMPANIES
 
Fatemeh Ardeshir Larijani
Honoraria - Binaytara; MJH Life Sciences; Picture Health; The National Cancer Institute's Central Institutional Review Board
Consulting or Advisory Role - Jasper Therapeutics; Value Based Medicine(IVBM)
Research Funding - Alira Health; American Philosophical Society; AstraZeneca; Discovery Grant Award, The Fund for Innovation in Cancer Informatics; Lung Cancer Research Award, Thoracic Surgery Foundation (Inst); Prevent Cancer Foundation grant award
Travel, Accommodations, Expenses - Binaytara; Bio Ascend